USPSTF Responds to Malecare’s Questions regarding PSA Screening
Malecare sent questions to Albert Siu, MD, Chairperson of the U.S. Preventive Services Task Force about plans to review their 2012 recommendation against the use of the PSA test for prostate cancer screening. We thought that [...]
The Financial Burden of Cancer Has Become A Toxicity Like Hair Loss And Nausea
My good friend and fellow advocate Mike Scott (Prostate Cancer Info Link) introduced me to a new web site produced by the University of Chicago called Cost of Care (www.CostofCare.org). The site is designed around [...]
Doing Away with Some of the Myths Surrounding Clinical Trials
Clinical trials are vital if we expect to continue to see improvements in the treatments and medications that are available. Unfortunately, there are some historical abuses in clinical trials so many people do approach them [...]
Dr. Crawford Questions ADT Standards Used in the Treatment of Men with Advanced Prostate Cancer
In an online article published Friday, November 6, 2015 Dr. David Crawford raises some very serious questions about how we standardly use hormone therapy (ADT) in the treatment of men with advanced prostate cancer. He [...]
Beware, A Potential Significant ADT Danger – Thromboembolic Disease
It has been long assumed that hormone therapy (ADT) used in the treatment of men with advanced prostate cancer increases a man’s risk for developing potentially live threatening thromboembolic disease (formation in a blood vessel [...]
Showing an Association Between RECIST Changes and Survival in Men with Castrate Resistant Prostate Cancer Receiving Chemotherapy
The Response Evaluation Criteria In Solid Tumors (RECIST) was first published in 2000 and then updated in 2009. RECIST is a set of published rules that attempt to define when cancer tumors, including prostate cancer tumors, [...]